Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

65.66 +0.98 (+1.52%)
Official Closing Price Updated: 7:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
37 38 Next >
How Is The Market Feeling About Bristol-Myers Squibb?
Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 4.42% since its last report. The company recently reported that it has 23.08 million shares sold short, which is 1.08% of all regular... 
Via Benzinga
Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio to be Presented at American Heart Association Scientific Sessions 2022
From Bristol Myers Squibb
Via Business Wire
Can Biotech Stocks Continue Rallying In This Bear Market?
Via Talk Markets
After FDA, European Agency Limits Use Of Certain JAK Inhibitors Amid Safety Concerns
 
Via Benzinga
Bristol Myers Squibb (BMY) Q3 2022 Earnings Call Transcript
BMY earnings call for the period ending September 30, 2022. 
Via The Motley Fool
Bristol Myers Snags Narrow Quarterly Beat, Keeps Outlook; But Shares Fall
One of the company's biggest products is facing continued challenges. 
Via Investor's Business Daily
Revlimid Generic Competition, Forex Impacts Bristol Myers' Q3 Sales; Reaffirms FY22 Guidance
 
Via Benzinga
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up. 
Via TheNewswire.com
Exposures Product Safety
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
By Mark Gilman, Benzinga 
Via News Direct
Exposures Product Safety
Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial
From Bristol Myers Squibb
Via Business Wire
MarketBeat: Week in Review 10/24-10/28
Stocks finished the week on a bullish note, and the MarketBeat analysts continue to guide you to the stocks and stories that are moving the market 
Via MarketBeat
Topics Economy Electric Vehicles
Exposures Economy Electric Vehicles Interest Rates
Analyst Sees Market Potential For Arcellx Multiple Myeloma Candidate, Sees 50% Upside In Stock
 
Via Benzinga
Wingstop To Rally Around 13%? Plus This Analyst Cuts PT On Cano Health By 50%
  Wedbush boosted the price target on Wingstop Inc. (NASDAQ: WING) from $157 to $177. Wedbush analyst Nick Setyan maintained an Outperform rating on the stock. Wingstop shares rose 0.8% to $156.66 on... 
Via Benzinga
If You Invested $10,000 in Bristol Myers Squibb 5 Years Ago, This Is How Much You Would Have Today
The stock has been beating the market this year -- and that says a lot. 
Via The Motley Fool
Where Bristol-Myers Squibb Stands With Analysts
Over the past 3 months, 6 analysts have published their opinion on Bristol-Myers Squibb (NYSE:BMY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding... 
Via Benzinga
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up.   
Via Benzinga
Is Bristol Myers Squibb Stock a Buy With Its New-Product Sales Soaring?
The biopharma company has a lot riding on its new drugs. 
Via The Motley Fool
Strong Fundamentals Make Bristol Myers Squibb Stock a Real Value
Bristol Myers Squibb stock posts results that establish it as an attractive value stock, even if it may not be as undervalued as it appeared before. 
Via MarketBeat
This Is What Whales Are Betting On Bristol-Myers Squibb
A whale with a lot of money to spend has taken a noticeably bullish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 17 strange trades. 
Via Benzinga
Big Tech Misses
Good Morning Everyone! Remember, the bigger the drawdown the better bigger the bounce. 
Via Benzinga
Two Warren Buffett Rules You Should Never Forget
Buffett's strategy for investing can be ideal for risk-averse investors. 
Via The Motley Fool
Nasdaq, S&P 500 Futures Lower Following Alphabet, Microsoft Earnings
Pre-open movers 
Via Benzinga
New Zeposia (ozanimod) Data Highlight COVID-19 Outcomes and Preservation of Long-Term Cognitive Function from Separate Analyses in Patients with Relapsing Forms of Multiple Sclerosis
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
From Bristol Myers Squibb
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
The Robert A. Winn Diversity in Clinical Trials Award Program Announces the Second Group of Physicians to be Trained in the $114 Million Program
From Bristol Myers Squibb
Via Business Wire
Cytokinetics CEO: Why It's OK Not Being An Overnight Success
The company hopes to come out next year with at least one heart-failure drug. 
Via Investor's Business Daily
2 Pharma Stocks With Blockbuster Drugs on the Horizon
Eli Lilly and Bristol Myers Squibb should benefit from two unique therapies. 
Via The Motley Fool
2 No-Brainer Healthcare Stocks to Buy Right Now
The healthcare industry is bursting with prime investment opportunities, even in the current environment. 
Via The Motley Fool
New Data Presented at the American College of Gastroenterology Annual Scientific Meeting Demonstrate Continuous Zeposia (ozanimod) Treatment Prevents Disease Relapse Over One Year in 86.1% of Patients Who Respond at the End of the Induction Period
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
37 38 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.